These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36649742)

  • 1. Nanomedicine based strategies for oligonucleotide traversion across the blood-brain barrier.
    Amulya E; Sikder A; Vambhurkar G; Shah S; Khatri DK; Raghuvanshi RS; Singh SB; Srivastava S
    J Control Release; 2023 Feb; 354():554-571. PubMed ID: 36649742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
    Zhao X; Ye Y; Ge S; Sun P; Yu P
    Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
    Tam VH; Sosa C; Liu R; Yao N; Priestley RD
    Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.
    Nafee N; Gouda N
    Curr Gene Ther; 2017; 17(2):154-169. PubMed ID: 28494740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
    Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
    Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles-based delivery system and its potentials in treating central nervous system disorders.
    Liu T; Xie Q; Dong Z; Peng Q
    Nanotechnology; 2022 Aug; 33(45):. PubMed ID: 35917704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation.
    May JN; Golombek SK; Baues M; Dasgupta A; Drude N; Rix A; Rommel D; von Stillfried S; Appold L; Pola R; Pechar M; van Bloois L; Storm G; Kuehne AJC; Gremse F; Theek B; Kiessling F; Lammers T
    Theranostics; 2020; 10(4):1948-1959. PubMed ID: 32042346
    [No Abstract]   [Full Text] [Related]  

  • 9. Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
    Furtado D; Björnmalm M; Ayton S; Bush AI; Kempe K; Caruso F
    Adv Mater; 2018 Nov; 30(46):e1801362. PubMed ID: 30066406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocarriers for Delivery of Oligonucleotides to the CNS.
    Male D; Gromnicova R
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicine based nanoparticles for neurological disorders.
    Sriramoju B; Kanwar RK; Kanwar JR
    Curr Med Chem; 2014; 21(36):4154-68. PubMed ID: 25039778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.
    Li J; Zheng M; Shimoni O; Banks WA; Bush AI; Gamble JR; Shi B
    Adv Sci (Weinh); 2021 Aug; 8(16):e2101090. PubMed ID: 34085418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-based nanoformulations in the treatment of neurological disorders.
    Pottoo FH; Sharma S; Javed MN; Barkat MA; Harshita ; Alam MS; Naim MJ; Alam O; Ansari MA; Barreto GE; Ashraf GM
    Drug Metab Rev; 2020 Feb; 52(1):185-204. PubMed ID: 32116044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective.
    Ashique S; Afzal O; Yasmin S; Hussain A; Altamimi MA; Webster TJ; Altamimi ASA
    Int J Pharm; 2023 Feb; 633():122614. PubMed ID: 36646255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostical application of nanomedicine for treating central nervous system disorders.
    Ran W; Xue X
    Sci China Life Sci; 2018 Apr; 61(4):392-399. PubMed ID: 29675554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano-enabled delivery systems across the blood-brain barrier.
    Hwang SR; Kim K
    Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoscale drug delivery systems and the blood-brain barrier.
    Alyautdin R; Khalin I; Nafeeza MI; Haron MH; Kuznetsov D
    Int J Nanomedicine; 2014; 9():795-811. PubMed ID: 24550672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal.
    Kanwar JR; Sun X; Punj V; Sriramoju B; Mohan RR; Zhou SF; Chauhan A; Kanwar RK
    Nanomedicine; 2012 May; 8(4):399-414. PubMed ID: 21889479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.